Motus' relamorelin hits anorexia, gastroparesis milestones

Motus Therapeutics Inc. presented Phase II proof-of-concept data for relamorelin ( RM-131) to treat anorexia nervosa, and said it completed enrollment of 396 patients in a Phase IIb trial of the ghrelin agonist to treat diabetic gastroparesis. Allergan plc (NYSE:AGN) has an exclusive option to acquire Motus when the gastroparesis trial is completed.

Motus President Bart Henderson declined to discuss a timeline for the gastroparesis study, and said terms of the option are undisclosed. ...